Switzerland Santen is a leading multinational company that specializes in ophthalmology. President and Head for Europe, Middle East and Africa (EMEA) Luis Iglesias highlights the company’s recent transformation through partnerships across a vast array of areas including digital technology and cell and gene. He also discusses how Santen has leveraged its…
Switzerland Swiss-headquartered ADIENNE has made recent headlines after being announced as the first European company to manufacture Russia’s Sputnik V COVID-19 vaccine. President and Founder Antonio Francesco Di Naro explains how the company’s deal with the Russian Direct Investment Fund happened and some of the challenges related to the manufacturing process.…
Switzerland In the last month alone, CDMO giant Lonza has announced three major upgrades to its manufacturing footprint in Visp, Western Switzerland: a huge expansion of its biologics capacity, new production lines for the manufacture of antibody-drug conjugates, and a ramping up of its workforce dedicated to the production of ingredients…
Switzerland Georg Boonen, CEO of Switzerland’s leading phytopharmaceutical player Max Zeller, discusses the company’s expanded market position at home and abroad, how COVID-19 and a reconsideration of preventive healthcare could be an inflection point for phytopharma, and what keeps him motivated after 22 years at the firm. COVID has led…
Switzerland The SXI Bio & MedTech Index outperformed the Swiss Performance Index (SPI) by 38 percent and NASDAQ Biotech by 46 per cent between 2015 and 2020. Key listings include Kuros Biosciences, Idorsia, Polyphor, ObsEva, and IGEA Pharma Made with Visme Infographic Maker To read more about the Swiss biotech investment…
Switzerland Animal testing for medicinal purposes is back under the spotlight in Switzerland after a petition against the practice filed in Bern managed to generate tens of thousands of signatures. Even more ominously, a popular initiative emanating from the Canton of St Gallen is still pending that proposes an outright ban…
Switzerland Vincent Gruntz looks at the market dynamics for oncology in Switzerland, where an increasingly cost-conscious approach is being taken to reimbursement and pricing, his experience of bringing CAR-T therapies to the country, and the challenges and opportunities of ‘virtual’ product launches. Once you have seen a patient – that…
Switzerland In February 2020, US giant MSD announced the launch of a new site in Zurich specialising in R&D, data management, and commercialisation, foregrounding the company’s commitment to Switzerland. MSD employs over 1000 people in Switzerland across five sites in local, regional, and global functions, engages in 25 in-country clinical trials…
Switzerland Biogen Switzerland’s Dr med Katharina Gasser outlines how her affiliate navigated the COVID-19 pandemic from an organisational and communication perspective, the increasing importance being given to mental health by the Swiss government, and the reimbursement and market challenges facing Biogen in 2021 and beyond. 2020 saw a lot of…
Switzerland Michael Altorfer, CEO of the Swiss Biotech Association, a membership organisation representing the interests of the Swiss biotech industry, discusses the evolution of the biotech sector in Switzerland, how the country’s ecosystem has helped foster success stories like Actelion, and the multilateral work being done to improve intellectual property protection…
Switzerland Antonella Santuccione Chadha*, Head of Stakeholder Engagement for Alzheimer’s disease at Biogen and co-founder and CEO of the Women’s Brain Project, dives into the non-profit organization’s role in rethinking the way we look at sex and gender as a gateway to precision medicine. She explains how artificial intelligence (AI) is…
Switzerland In a recent conversation with PharmaBoardroom, Michael Sidler of Redalpine Venture Partners, a venture capital (VC) firm aiming to support founders and start-ups in Europe, highlighted how the European VC & the Switzerland Biotech Investment space has evolved over the past decade and the funding challenges that remain. He also…
See our Cookie Privacy Policy Here